Cognivia announced a new name for the company formerly known as Tools4Patient. The transition to Cognivia more closely reflects the company's mission to “quantify the power of the mind” and integrate this information into data analyses to optimize and accelerate drug development.
This name change expresses the evolution of the company since it was founded eight years ago. As part of this maturation, Cognivia has built the evidence basis for its technologies through multiple clinical trials and has become a partner of pharma companies, biotechs, and CROs. Cognivia’s solutions are focused in areas that have posed significant challenges to drug development, including the placebo response and medication adherence in clinical trials.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.